Additional Strategic Funding for CartiHeal’s Ongoing AGILI-C™ IDE Clinical Study
By a
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180131005840/en/
Bioventus's
The funding will focus on CartiHeal's ongoing Agili-C IDE clinical study. Further to the trial's initiation 3 months ago, over thirty patients were already enrolled, according to enrollment rate forecasts.
CartiHeal CEO,
"Agili-C shows great promise to relieve osteoarthritis pain for a large patient population and we look forward following the pivotal trial to a successful culmination," said
Bioventus and the Bioventus logo are registered trademarks of
Keywords for this news article include: Business, Bioventus,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
Unum Group Reports Fourth Quarter 2017 Results
Findings from HEC Montreal in the Area of Healthcare Economics Described (Individual survival curves comparing subjective and observed mortality…
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News